

	Name of the Issue: Go Digit General In				
1	Type of Issue	Initial Public Off			
2	Issue Size (Rs. Mn)	26146.46	<b>)</b> *		
	*Source: Prospectus dated May 17, 2024				
3	Grade of issue along with name of the				
	Name	NA			
	Grade	NA			
4	Subscription Level (Number of times)	10.0	3*		
	*The above figure is after removing multi	ple or duplicate Bids			
	*Source: Final post issue report dated Ma	ay 27, 2024			
5	QIB Holding (as a %age of Outstanding	g Capital) as disclosed to the stoc	k exchanges		
	Particulars		%		
	(i) On Allotment**		19.09%		
		aby ofter the listing	13.0370		
	(ii) at the end of the 1st Quarter immediat		21.32%		
	of the issue (June 30, 2024) *	-			
	(iii) at the end of 1st FY (March 31, 2025)		Not Available		
	(iv) at the end of 2nd FY (March 31, 2026	,	Not Available		
	(v) at the end of 3rd FY (March 31, 2027)		Not Available		
	**Reporting with the BSE. Represents ho				
	* QIB Holding not disclosed as reporting	for relevant period has not been con	npleted.		
6	Financials of the issuer				
	Parameters	1st FY (March 31,2025)*	2nd FY (March	3rd FY (March	
	Income from operations	Not Available	31,2026)* Not Available	31,2027)*	
	Income from operations			Not Available	
	Net Profit/(Loss) for the period	Not Available	Not Available	Not Available	
	Paid-up equity share capital	Not Available	Not Available	Not Available	
	Reserves excluding revaluation	Not Available	Not Available	Not Available	
	reserves				_
	* Financials not available as reporting for	the relevant years has not been col	mpleted.		
7	Trading Status				
	The equity shares of Mankind Pharma Lin ("NSE") (and together with BSE the "Stoo		nited ("BSE") and the N	ational Stock Exchar	ge
	The equity shares have not been suspen	ded or delisted.			
	Particulars		Status		
	(i) at the end of 1st FY (March 31, 2025)*		Not Available		
	(ii) at the end of 2nd FY (March 31, 2026)	)*	Not Available		

(iii) at the end of 3rd FY (March 31, 2027)\* Not Available \* Trading status not disclosed as the relevant fiscal years have not been completed.



0	Change in Directors of Issuer from the disclosu	res in the offer document			
F	Particulars	Name of Director	Appointed / Resigned		
`	i) at the end of 1st FY (March 31, 2025)*	Not Available	Not Applicable		
`	ii) at the end of 2nd FY (March 31, 2026)*	Not Available	Not Available		
``	iii) at the end of 3rd FY (March 31, 2027)*	Not Available	Not Available		
*	* Changes in Directors of Issuer not updated as the	relevant financial years have	not been complete		
S	Status of implementation of project/ commencement of commercial production				
(i	i) as disclosed in the offer document	Ν	lot applicable		
(	ii) Actual implementation	Ν	lot applicable		
(	iii) Reasons for delay in implementation, if any	Ν	lot applicable		

## 10 Status of utilization of issue proceeds

(i) as disclosed in the offer document		In Million
Particulars	Amount proposed to be financed from Net Proceeds	Estimated Utilisation of Net Proceeds in Fiscal 2025
Investments to maintain solvency ratio	10647.00	10647.00
General Corporate Purposes	-	-
Total Proceeds Source: Prospectus dated May 17, 2024	10647.00	10647.00

Particulars	Amount proposed to be financed from Net Proceeds	Actual Utilisation of Net Proceeds	Unutilised Net Proceeds
Investments to maintain solvency ratio	10647.00	0.00	10647.00
General corporate purposes	-	-	-
Total Proceeds	10647.00	0.00	10647.00
(iii) Reasons for delay in implementation, if any		Not applicable	



11 Comments of monitoring agency, if applicable

There has been no deviation. The nil statement under regulation 32 of SEBI Listing Regulation in this regard has been reviewed by Audit Committee at its meeting held on 25th July 2024. Not applicable Not applicable

(i) Comments on use of funds

(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document (iii) Any other reservations expressed by the monitoring agency about the end use of funds

Pricing Data						
Designated Stock Exchange	NSE					
Issue Price (Rs.)	272.00					
Listing Date	23-May-24	22-Jun-24	21-Aug-24			
Price parameters	At close of listing day- 23-05-2024	Close of 30th calendar day	Close of 90th calendar day from	As at the end of th	of the 1nd FY after the listing of the issu March,2025) <sup>(1)</sup>	
		from listing day	listing day	<b>Closing price</b>	High	Low
Market Price	306.00	334.10	358.25	Not Available	Not Available	Not Available
Nifty 50*	22,967.65	23,501.10	24,770.20	Not Available	Not Available	Not Available

Price parameters	As at the end of the 2nd FY after	the listing of the issue	e (31st March,2026) <sup>(1</sup>	$_{\rm b}$ As at the end of the	s at the end of the 3rd FY after the listing of the issue (31s March,2027) <sup>(1)</sup>			
	Closing price	High	Low	Closing price	High	Low		
Market Price	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available		
Nifty 50*	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available		

\* Being index of NSE, the designated stock exchange

(1) The pricing data is not disclosed as the relevant fiscal years have not been completed

(2) Closing prices have been considered. In case of the date falling on holiday, previous working day has been considered



## 13 Basis for Issue Price

Accounting ratio		Face Value per As disc share (Rs.) docum	closed in offer ent*	At the end of 1st A FY (March 31,2025)**	t the end of 1st FY (March 31,2026)**	At the end of 1st FY (March 31,2027)**
	Company					
	Consolidated	10	0.40	Not Available	Not Available	Not Available
	Peer Group:					
	New India Assurance Company	5	6.36			
EPS (Diluted)	Limited	5	0.50			
	Star Health and Allied Insurance	10	10.41	Not Available	Not Available	Not Available
	Company Limited	10	10.41	NUL AVAIIADIE		Not Available
	ICICI Lombard General Insurance	10	35.16	Not Available	Not Available	Not Available
	Company Ltd					
	Industry Avg		17.31	Not Available	Not Available	Not Available
	Company					
	Consolidated		NA	Not Available	Not Available	Not Available
	Peer Group:					
	New India Assurance Company		38.47	Not Available	Not Available	Not Available
P/E	Limited		50.47	Not Available	Not Available	Not Available
.,_	Star Health and Allied Insurance		53.79	Not Available	Not Available	Not Available
	Company Limited		55.15	Not Available	Not Available	Not Available
	ICICI Lombard General Insurance		48.14	Not Available	Not Available	Not Available
	Company Ltd					
	Industry Avg		46.80	Not Available	Not Available	Not Available
	Company					
	Consolidated		1.53%	Not Available	Not Available	Not Available
	Peer Group:					
	New India Assurance Company		5.13%	Not Available	Not Available	Not Available
RoNW	Limited		0.1070	Not Available		
	Star Health and Allied Insurance		11.39%	Not Available	Not Available	Not Available
	Company Limited		11.0070			
	ICICI Lombard General Insurance		16.64%	Not Available	Not Available	Not Available
	Company Ltd					
	Industry Avg		11.05%	Not Available	Not Available	Not Available



	Company				
	Consolidated	26.61	Not Available	Not Available	Not Available
	Peer Group:				
NAV not chore	New India Assurance Company Limited	125.64	Not Available	Not Available	Not Available
NAV per share	Star Health and Allied Insurance Company Limited ICICI Lombard General Insurance Company Ltd	93.35	Not Available	Not Available	Not Available
		211.60	Not Available	Not Available	Not Available
	Industry Avg	143.53	Not Available	Not Available	Not Available

Notes

\* Sourced from Prospectus dated May 17, 2024.

\*\*Not available as the relevant fiscal years have not been completed / information not disclosed

## 14 Any other material information

Particulars	Date	Remarks
For further updates and information, please refer stock exchange websites i.e. www.bseindia.com and www.nseindia.com		

Source: Stock Exchange filings